Busulfan intravenous - Otsuka Pharmaceutical

Drug Profile

Busulfan intravenous - Otsuka Pharmaceutical

Alternative Names: Busilvex; Busulfan injection - Orphan Medical; Busulfex; IV busulfan - Otsuka; KRN 246

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Orphan Medical; PDL BioPharma
  • Developer Kirin Holdings Company; Orphan Medical; Tzamal Pharma
  • Class Antineoplastics; Butylene glycols; Glycols; Mesylates; Myeloablative agonists; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haematological malignancies

Most Recent Events

  • 25 Jul 2016 Busulfan intravenous licensed to Grupo Biotoscana in Colombia, Chile, Ecuador and Peru
  • 15 Mar 2016 Biomarkers information updated
  • 01 Apr 2015 European Group for Blood and Marrow Transplantation terminates the phase RICMAC III trial for Acute myeloid leukaemia and Myelodysplastic syndromes in Finland, Belgium, Germany, Italy, the Netherlands, Russia and the UK (NCT01203228)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top